Proceedings from the September 26, 2020, Hospital Medicine Summit

 

 

 

PROGRAM OVERVIEW

The 2020 Hospital Medicine Summit (HMS) is an innovative, multisupported, multifaceted educational initiative designed to provide important educational updates from leading experts on conditions that are commonly encountered by healthcare clinicians practicing in the hospital and internal medicine settings.

This Hospital Medicine Summit Proceedings Monograph summarizes recent clinical trial data, practical strategies and detailed discussions presented by leading experts during the September 26, 2020 virtual symposium.

PROGRAM CHAIR

Alpesh Amin, MD, MBA, FACC, MACP, SFHM
Thomas & Mary Cesario Chair of Medicine
Professor of Medicine, Business, Public Health, Nursing Science, and Biomedical Engineering
Executive Director, Hospitalist Program
Medical Director, Anticoagulation Services
University of California, Irvine
Irvine, California

Editorial Assistance:

Kathleen Wildasin, MA
Medical/Science Writer
Lexington, Kentucky

 

Release date: December 30, 2020
Expiration date: December 30, 2021
Estimated time to complete activity: 2.0 hours

 

TARGET AUDIENCE

This educational initiative has been designed for physicians, physician assistants, nurse practitioners, registered nurses, and pharmacists who practice in hospital and internal medicine settings.

LEARNING OBJECTIVES

Drift, Shift, Evolve: Keeping Abreast of the Role of Antiviral Therapy in the Management of Seasonal Influenza

  • Appraise the role of vaccination in reducing the spread of influenza and improving patient outcomes
  • Employ updated guidelines for the diagnosis of influenza in the hospitalized patient
  • Determine appropriate use of antiviral chemoprophylaxis for individuals at risk of influenza and associated complications
  • Compare current and emerging antiviral agents based on efficacy and safety, dosage and administration, and reduction in duration of illness and complications in order to make individualized treatment decisions for patients with influenza

Assessment and Management of Hyperkalemia in the Hospital Setting: Optimizing Patient Outcomes

  • Identify factors that increase risk for hyperkalemia
  • Discuss the relationship between renin-angiotensin system (RAAS) inhibitors and hyperkalemia development in patients with chronic kidney disease, heart failure, hypertension, and/or diabetes mellitus
  • Apply to practice an understanding of clinical trial evidence for the efficacy and safety of newer potassium binders approved for treating hyperkalemia
  • Employ a multidisciplinary, team-based approach to improve outcomes for patients with hyperkalemia

Optimizing Transitions from Hospital to Home: Best Practices for Reducing Readmissions in Heart Failure

  • Apply diagnostic and assessment criteria to the effective management of patients with heart failure (HF)
  • Integrate current guideline-directed medical therapy (GDMT) and recent clinical trial outcomes into the effective management of patients with HF
  • Develop a comprehensive GDMT approach to HF management in patients who have recently experienced an acute heart failure episode
  • Review proven strategies to achieve successful transitions of care in patients with HF

The Impact of COVID-19 on Hospital Medicine

  • Discuss the impact of COVID-19 on hospital-based practice in the US
  • Describe lessons learned in hospital surge and emergency medical preparedness
  • Review and highlight key successes in the US healthcare system response to COVID-19
ACCREDITATION
PHYSICIAN CONTINUING EDUCATION

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

PHARMACIST CONTINUING EDUCATION

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-20-077-H01-P.)

This is a knowledge-based activity.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 2.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME/CE credit for this activity.

During the period of December 30, 2020 through December 30, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Pharmacists must check the CPE monitor for their credits within 60 days of the activity.

MEDIA

Internet and Print

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or hms@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below

Click here for more information on minimum system requirements.

DISCLOSURE OF CONFLICTS OF INTEREST (COI)

Integrity Continuing Education and Global Education Group requires instructors, planners, managers and other individuals who are in a position to control the content of this activity and their spouse/life partner to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education and Global Education Group for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Program Chair Disclosures

Dr. Alpesh Amin, MD, MBA, FACC, MACP, SFHM

  • COVID-19 Trials PI/Co-I – Alexion, Blade Therapeutics, Eli Lilly, Fulcrum Therapeutics, Humanigen, NIH/NIAID, NeuroRx Pharma, Novartis, OctaPharma, PTC Therapeutics, Pulmotect, Takeda
  • Consulting Fees – AstraZeneca
  • Ownership Interest – AseptiScope, Sprightly Health

The following planners and managers (along with their spouses/life partners) reported no financial relationships nor relationships to products or devices with commercial interests related to the content of this CME activity: Lindsay Borvansky, Rachel Brown, PharmD, MPH, Ashley Cann, Andrea Funk, Donna Fausak, Liddy Knight, Ashley Marostica, RN, MSN, Michelle R. Rizzo, ELS, Patima Tanapat, PhD, Kathleen Wildasin, MA.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.

This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Genentech, a member of the Roche Group, and Novartis Pharmaceuticals Corporation.

Continue to Pretest